Shield Therapeutics PLC Shield to Present at Baird Healthcare Conference (3693P)
August 31 2017 - 1:01AM
UK Regulatory
TIDMSTX
RNS Number : 3693P
Shield Therapeutics PLC
31 August 2017
Shield Therapeutics plc to Present at the Baird Global
Healthcare Conference on Wednesday, September 6, 2017
London, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a
specialty pharmaceutical company focused on secondary care, today
announced that Carl Sterritt, Chief Executive Officer, will present
at the Baird Global Healthcare Conference on Wednesday, September
6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a
corporate overview, review the Company's late-stage and commercial
product portfolio, and provide an update on upcoming milestones,
including key clinical trial readouts and potential subsequent
regulatory submission.
An audio webcast of the presentation will be available in the
events section of the Company's website, or by clicking here. A
replay will be available for a limited time following the
presentation.
About Shield Therapeutics
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals, which address areas of unmet
medical need. The Group has a marketed product, Feraccru(R), for
the treatment of IDA in adult patients with IBD which has exclusive
IP rights until the mid-2030's. In addition, the Group is
developing PT20, a late-stage pharmaceutical for the treatment of
systemic phosphate accumulation (hyperphosphatemia). Shield
Therapeutics, headquartered in London, is listed on LSE's AIM under
the ticker STX. For more information please visit
www.shieldtx.com.
For further information please contact:
Shield Therapeutics plc +44 (0) 207 186 8500
Joanne Estell, Chief Financial Officer
Karl Keegan, Corporate Development Director
Nominated Adviser and Joint Broker +44 (0)20 3100 2222
Liberum Capital Limited
Christopher Britton
Steve Pearce
Jonathan Wilkes-Green
Joint Broker +44 (0)20 7418 8900
Peel Hunt LLP
James Steel
Alastair Rae
Oliver Jackson
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
shieldtherapeutics@consilium-comms.com
U.S Investor Relations + 1 (212)-599-1265
Lazar Partners Ltd.
Matthew Ventimiglia
mventimiglia@lazarpartners.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMGFRMGFGNZZ
(END) Dow Jones Newswires
August 31, 2017 02:01 ET (06:01 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024